Close Menu

SAN FRANCISCO (GenomeWeb) – Natera said it is on track for an end of the year or early 2019 launch of a clinical version of its circulating tumor DNA assay Signatera and that it planned to eventually submit it to both the US Food and Drug Administration and the Centers for Medicare and Medicaid Services.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.